Rimiducid
Based on 58 publication(s) in Google Scholar
Rimiducid (AP1903) is a dimerizer agent that acts by cross-linking the FKBP domains. Rimiducid (AP1903) dimerizes the Caspase 9 suicide switch and rapidly induces apoptosis.
For research use only. We do not sell to patients.
- Purity: 99.94%
- CAS No.: 195514-63-7
- Formula: C78H98N4O20
- Molecular Weight:1411.63
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Rimiducid
More- Nat Biotechnol. 2025 Sep 10. [Abstract]
- Nat Biomed Eng. 2022 Jul;6(7):842-854. [Abstract]
- Nat Commun. 2024 May 13;15(1):4026. [Abstract]
- Nat Commun. 2023 Jun 20;14(1):3642. [Abstract]
- Nat Commun. 2022 Dec 6;13(1):7522. [Abstract]
- Nat Commun. 2021 Dec 8;12(1):7114. [Abstract]
- Nat Commun. 2020 Apr 2;11(1):1625. [Abstract]
- Neuron. 2026 Mar 11:S0896-6273(26)00086-3. [Abstract]
- Nat Chem Biol. 2023 Aug;19(8):981-991. [Abstract]
- Nat Chem Biol. 2022 Apr;18(4):360-367. [Abstract]
- Nucleic Acids Res. 2020 Jan 10;48(1):e1. [Abstract]
- Adv Sci (Weinh). 2025 Aug 22:e17677. [Abstract]
- Sci Adv. 2026 Feb 6;12(6):eadz3483. [Abstract]
- Sci Adv. 2025 Jun 27;11(26):eadx3011. [Abstract]
- Mol Ther. 2026 Jan 10:S1525-0016(26)00001-8. [Abstract]
- Genome Med. 2021 Oct 14;13(1):165. [Abstract]
- Nat Struct Mol Biol. 2025 Apr;32(4):625-638. [Abstract]
- Genome Biol. 2023 Feb 24;24(1):36. [Abstract]
- Chin Med J (Engl). 2024 Nov 5;137(21):2590-2602. [Abstract]
- Cell Chem Biol. 2025 Oct 22:S2451-9456(25)00306-X. [Abstract]
- Mol Ther Oncol. 2025 Nov 22;33(4):201104. [Abstract]
- Am J Hum Genet. 2020 Jul 2;107(1):111-123. [Abstract]
- Cell Prolif. 2023 May;56(5):e13471. [Abstract]
- Mol Syst Biol. 2024 May;20(5):481-505. [Abstract]
- Stem Cells Transl Med. 2020 Nov;9(11):1378-1388. [Abstract]
- Int Immunopharmacol. 2020 Nov;88:106860. [Abstract]
- Mol Ther Methods Clin Dev. 2021 Mar 5:21:171-179. [Abstract]
- PLoS Pathog. 2021 Jul 16;17(7):e1009715. [Abstract]
- Sci Rep. 2021 Jun 1;11(1):11407. [Abstract]
- Sci Rep. 2019 Mar 6;9(1):3630. [Abstract]
- FEBS J. 2025 May 20. [Abstract]
- STAR Protoc. 2026 Apr 24;7(2):104523. [Abstract]
- bioRxiv. 2026 May 1:2026.04.28.721489. [Abstract]
- bioRxiv. 2026 May 14.
- Washington University in St. Louis. 2026.
- bioRxiv. 2026 Mar 16:2026.03.12.711465. [Abstract]
- bioRxiv. 2026 Jan 18:2026.01.16.699909. [Abstract]
- bioRxiv. 2025 Oct 3.
- Patent. US20250161288A1.
- bioRxiv. 2025 May 17.
- bioRxiv. 2025 May 30.
- bioRxiv. 2025 May 15:2025.05.10.653233. [Abstract]
- bioRxiv. 2025 April 24.
- Patent. US20240335470A1.
- bioRxiv. 2024 Mar 27:2024.03.21.585809. [Abstract]
- medRxiv. 2023 Dec 20:2023.12.19.23299592. [Abstract]
- bioRxiv. 2023 Oct 2.
- bioRxiv. 2023 Jun 7:2023.06.06.543963. [Abstract]
- bioRxiv. 2023 Jun 8.
- bioRxiv. 2023 Apr 29:2023.04.28.538612. [Abstract]
- Patent. US20230070866A1.
- Patent. US20220177911A1.
- bioRxiv. January 06, 2022.
- Patent. US20210260125A1.
- University of Minnesota. 2021 Jul.
- Patent. US20200095604A1
- Patent. US20190271005A1.
- Patent. US20180155717A1.
Customer Validation & Images
-
WB
-
Cell Imaging/Staining
-
WB
-
RT-PCR
-
In Vivo Efficacy Study
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HT-1080 | EC50 |
2 nM
Compound: 1i(dimer)
|
Compound was induced transcription stably transfected with constructs encoding separate DNA-binding domain and activation domain proteins in HT1080 human fibrosarcoma cells
Compound was induced transcription stably transfected with constructs encoding separate DNA-binding domain and activation domain proteins in HT1080 human fibrosarcoma cells
|
[PMID: 12951089] |
| HT-1080 | EC50 |
3 nM
Compound: 1b (AP1903)(dimer)
|
Compound was induced transcription in transiently transfected with constructs encoding separate DNA-binding domain and activation domain proteins in HT1080 human fibrosarcoma cells
Compound was induced transcription in transiently transfected with constructs encoding separate DNA-binding domain and activation domain proteins in HT1080 human fibrosarcoma cells
|
[PMID: 12951089] |
Rimiducid (AP1903) elicits potent and dose-dependent apoptotic death of these engineered cells in culture, with an EC50 of ≈0.1 nM[1]. Maximal killing occurred in the presence of 3 to 10 nM Rimiducid (AP1903), and the IC50 is approximately 0.2 nM. LV′VFas-transduced T lymphocytes expressing high levels of CD25 (top panel) are eliminated by with 66%±7.5% (n=10) efficiency. When cells are examined after CD25 expression returned to basal levels, 63%±4.7% (n=9) killing is observed after Rimiducid treatment[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 195514-63-7
-
Appearance Solid
-
Molecular Weight 1411.63
-
Formula C78H98N4O20
-
Color White to light yellow
-
SMILES
COC1=CC=C(CC[C@@H](OC([C@@H]2CCCCN2C([C@@H](CC)C3=CC(OC)=C(OC)C(OC)=C3)=O)=O)C4=CC=CC(OCC(NCCNC(COC5=CC([C@@H](CCC6=CC=C(OC)C(OC)=C6)OC([C@@H]7CCCCN7C([C@H](C8=CC(OC)=C(OC)C(OC)=C8)CC)=O)=O)=CC=C5)=O)=O)=C4)C=C1OC
-
Synonyms
AP1903
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (58)
-
Journal Impact Factor
-
Most Recent
-
Nat Biotechnol
A rapid imaging-based screen for induced-proximity degraders identifies a potent degrader of oncoprotein SKP2. [Abstract]2025 Sep 10. PMID: 40931108 -
Nat Biomed Eng
Synthetic libraries of immune cells displaying a diverse repertoire of chimaeric antigen receptors as a potent cancer immunotherapy. [Abstract]2022 Jul;6(7):842-854. PMID: 35668107 -
Nat Commun
Deep mutational scanning reveals a correlation between degradation and toxicity of thousands of aspartoacylase variants. [Abstract]2024 May 13;15(1):4026. PMID: 38740822 -
Nat Commun
Chimeric antigen receptor T cells targeting FcRH5 provide robust tumour-specific responses in murine xenograft models of multiple myeloma. [Abstract]2023 Jun 20;14(1):3642. PMID: 37339964 -
Nat Commun
The dynamic clustering of insulin receptor underlies its signaling and is disrupted in insulin resistance. [Abstract]2022 Dec 6;13(1):7522. PMID: 36473871
Rimiducid purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Dec 6;13(1):7522. [Abstract]
Representative images of IR-FKBP in cells after treatment with DMSO or AP1903 (5 μM) for 16 hours.
Rimiducid purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Dec 6;13(1):7522. [Abstract]
Immunoblot and quantification for phosphorylated IR-FKBP (pIR-FKBP) and pIRS1 over total protein. Cells expressing IR-FKBP were treated with DMSO (light blue) or AP1903 (red) for 16 h. Six biological replicates were analyzed for DMSO and AP1903-treated cells.
-
Nat Commun
Probing ion channel functional architecture and domain recombination compatibility by massively parallel domain insertion profiling. [Abstract]2021 Dec 8;12(1):7114. PMID: 34880224 -
Nat Commun
Dual functions of Aire CARD multimerization in the transcriptional regulation of T cell tolerance. [Abstract]2020 Apr 2;11(1):1625. PMID: 32242017
Rimiducid purchased from MedChemExpress. Usage Cited in: Nat Commun. 2020 Apr 2;11(1):1625. [Abstract]
Transcriptional activity of ∆CARD fused with 1–4 tandem repeats of FKBP (FKBP1–4) in the presence and absence of AP1903. Fusion constructs were transiently expressed (using 1.25 μg/ml DNA) in 293 T cells and DMSO or AP1903 (5 μM) was added 24 h later. Cells were harvested 48 h after transfection, followed by RT-qPCR of the respective Aire-dependent genes (represented by CD4 and IGFL1). The relative mRNA level of an Aire-independent gene, HPRT1, was also shown as a negative control.
Rimiducid purchased from MedChemExpress. Usage Cited in: Nat Commun. 2020 Apr 2;11(1):1625. [Abstract]
AP1903 (5 mg/kg) was administered intraperitoneally on days 11 and 14. Tumor growth curves of mice in different treatment groups.
-
Neuron
Targeting PGAM5-driven mitochondrial integrated stress response slows ALS progression across subtypes. [Abstract]2026 Mar 11:S0896-6273(26)00086-3. PMID: 41819100 -
Nat Chem Biol
2023 Aug;19(8):981-991. PMID: 36879061 -
Nat Chem Biol
2022 Apr;18(4):360-367. PMID: 34857958 -
Nucleic Acids Res
An improved platform for functional assessment of large protein libraries in mammalian cells. [Abstract]2020 Jan 10;48(1):e1. PMID: 31612958 -
Adv Sci (Weinh)
Lifespan-Regulated CAR-Macrophages from Myeloid Progenitors for Enhanced Colorectal Cancer Therapy. [Abstract]2025 Aug 22:e17677. PMID: 40847445
Rimiducid purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Aug 22:e17677. [Abstract]
Western blotting analysis of apoptotic ratios and related apoptotic proteins in FcγRI‐CAR‐HMs with or without iCas9 after a 6 h exposure to AP1903 (10 ng/mL).
-
Sci Adv
2026 Feb 6;12(6):eadz3483. PMID: 41650254 -
Sci Adv
Large-scale experimental assessment of variant effects on the structure and function of the citrate transporter SLC13A5. [Abstract]2025 Jun 27;11(26):eadx3011. PMID: 40577459 -
Mol Ther
IL-18 metabolically reprograms CAR-expressing natural killer T cells and enhances their antitumor activity. [Abstract]2026 Jan 10:S1525-0016(26)00001-8. PMID: 41520178 -
Genome Med
Integrating thousands of PTEN variant activity and abundance measurements reveals variant subgroups and new dominant negatives in cancers. [Abstract]2021 Oct 14;13(1):165. PMID: 34649609 -
Nat Struct Mol Biol
Importance of an N-terminal structural switch in the distinction between small RNA-bound and free ARGONAUTE. [Abstract]2025 Apr;32(4):625-638. PMID: 39774835 -
Genome Biol
DIMPLE: deep insertion, deletion, and missense mutation libraries for exploring protein variation in evolution, disease, and biology. [Abstract]2023 Feb 24;24(1):36. PMID: 36829241 -
Chin Med J (Engl)
Development of a novel HER2-CAR monocyte cell therapy with controllable proliferation and enhanced anti-tumor efficacy. [Abstract]2024 Nov 5;137(21):2590-2602. PMID: 38243698 -
Cell Chem Biol
STT3A is essential for Wnt signaling and represents a target for cancers driven by RNF43 deficiency. [Abstract]2025 Oct 22:S2451-9456(25)00306-X. PMID: 41130209 -
Mol Ther Oncol
Using the iCasp9 suicide strategy to control the growth and function of genome-edited B cells with redirected antigen specificity. [Abstract]2025 Nov 22;33(4):201104. PMID: 41438137 -
Am J Hum Genet
2020 Jul 2;107(1):111-123. PMID: 32533946 -
Cell Prolif
Genome editing HLA alleles for a pilot immunocompatible hESC line in a Chinese hESC bank for cell therapies. [Abstract]2023 May;56(5):e13471. PMID: 37199039 -
Mol Syst Biol
Integrated multiplexed assays of variant effect reveal determinants of catechol-O-methyltransferase gene expression. [Abstract]2024 May;20(5):481-505. PMID: 38355921 -
Stem Cells Transl Med
Precision installation of a highly efficient suicide gene safety switch in human induced pluripotent stem cells. [Abstract]2020 Nov;9(11):1378-1388. PMID: 32662231 -
Int Immunopharmacol
Panax notoginseng saponin R1 modulates TNF-α/NF-κB signaling and attenuates allergic airway inflammation in asthma. [Abstract]2020 Nov;88:106860. PMID: 32771949 -
Mol Ther Methods Clin Dev
Improved safety of induced pluripotent stem cell-derived antigen-presenting cell-based cancer immunotherapy. [Abstract]2021 Mar 5:21:171-179. PMID: 33816647 -
PLoS Pathog
Mutants of human ACE2 differentially promote SARS-CoV and SARS-CoV-2 spike mediated infection. [Abstract]2021 Jul 16;17(7):e1009715. PMID: 34270613 -
Sci Rep
A selective cytotoxic adenovirus vector for concentration of pluripotent stem cells in human pluripotent stem cell-derived neural progenitor cells. [Abstract]2021 Jun 1;11(1):11407. PMID: 34075124 -
Sci Rep
Development of selective cytotoxic viral vectors for concentration of undifferentiated cells in cardiomyocytes derived from human induced pluripotent stem cells. [Abstract]2019 Mar 6;9(1):3630. PMID: 30842516 -
FEBS J
Extreme multivalency and a composite short linear motif facilitate PCNA-binding, localisation and abundance of p21 (CDKN1A). [Abstract]2025 May 20. PMID: 40392971 -
STAR Protoc
2026 Apr 24;7(2):104523. PMID: 42033729 -
bioRxiv
2026 May 1:2026.04.28.721489. PMID: 42094376 -
-
-
bioRxiv
Biophysical trade-offs in antibody evolution are resolved by conformation-mediated epistasis. [Abstract]2026 Mar 16:2026.03.12.711465. PMID: 41889954 -
bioRxiv
2026 Jan 18:2026.01.16.699909. PMID: 41648336 -
-
-
-
-
bioRxiv
2025 May 15:2025.05.10.653233. PMID: 40463067 -
-
-
bioRxiv
Mutational scanning of CRX classifies clinical variants and reveals biochemical properties of the transcriptional effector domain. [Abstract]2024 Mar 27:2024.03.21.585809. PMID: 38585983 -
medRxiv
Multi-site validation of a functional assay to adjudicate SCN5A Brugada Syndrome-associated variants. [Abstract]2023 Dec 20:2023.12.19.23299592. PMID: 38196587 -
-
bioRxiv
The full spectrum of OCT1 (SLC22A1) mutations bridges transporter biophysics to drug pharmacogenomics. [Abstract]2023 Jun 7:2023.06.06.543963. PMID: 37333090 -
-
bioRxiv
High-throughput functional mapping of variants in an arrhythmia gene, KCNE1, reveals novel biology. [Abstract]2023 Apr 29:2023.04.28.538612. PMID: 37162834 -
-
-
-
-
-
-
-
Solvent & Solubility
DMSO : ≥ 100 mg/mL (70.84 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
Cloned HT1080 cell lines (ATCC CCL-121) retrovirally transduced with Fas constructs are prepared. Cell viability after overnight incubation with Rimiducid (0.01 nM, 0.1 nM, 1 nM, 10 nM, 100 nM, 1000 nM) is measured by Alamar Blue assay[1]. For annexin V assays, sorted LV′VFas-transduced T cells (2×106 cells/mL) are incubated with 10 nM Rimiducid. Analyzed by flow cytometry[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mice[1]
Male nu/nu mice are used. For injection, HTFasGH-3 cells are harvested from tissue culture dishes in PBS/0.1% glucose/10 mM EDTA, washed, and resuspended in PBS/0.1% BSA/0.1% glucose at a concentration of 2×107 cells/mL. Between 2 and 4×106 cells are implanted into two i.m. sites. After 24 h, mice are administered i.v. Rimiducid at 2 mL/kg. After a further 24 h mice are killed and serum human GH concentrations are determined by ELISA.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
References
[1]. Clackson T, et al. Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity. Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10437-42. [Content Brief]
[2]. Thomis DC, et al. A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. Blood. 2001 Mar 1;97(5):1249-57. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.7084 mL | 3.5420 mL | 7.0840 mL | 17.7100 mL |
| 5 mM | 0.1417 mL | 0.7084 mL | 1.4168 mL | 3.5420 mL | |
| 10 mM | 0.0708 mL | 0.3542 mL | 0.7084 mL | 1.7710 mL | |
| 15 mM | 0.0472 mL | 0.2361 mL | 0.4723 mL | 1.1807 mL | |
| 20 mM | 0.0354 mL | 0.1771 mL | 0.3542 mL | 0.8855 mL | |
| 25 mM | 0.0283 mL | 0.1417 mL | 0.2834 mL | 0.7084 mL | |
| 30 mM | 0.0236 mL | 0.1181 mL | 0.2361 mL | 0.5903 mL | |
| 40 mM | 0.0177 mL | 0.0886 mL | 0.1771 mL | 0.4428 mL | |
| 50 mM | 0.0142 mL | 0.0708 mL | 0.1417 mL | 0.3542 mL | |
| 60 mM | 0.0118 mL | 0.0590 mL | 0.1181 mL | 0.2952 mL |
Rimiducid Related Classifications
HY-16046 Related Classifications
Powered by Bioz